IL-17 Antagonistic Antibodies
US 7,807,155 In forceTerm ends May 4, 2030 · Low confidence
20-year base term ended Aug 4, 2025
Aug 4, 2005
May 4, 2030
Oct 5, 2010
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Aug 4, 2005, when the earliest non-provisional application in its chain was filed (this one was filed Mar 2, 2007) | Aug 4, 2025 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +721 days, USPTO patent term adjustment record | Jul 26, 2027 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,807,155) | resolves to Jul 26, 2027, no earlier than this term, so no change | High confidence |
| Patent term extension | +1013 days, USPTO 35 U.S.C. 156 certificate | added to Jul 26, 2027: May 4, 2030 | High confidence |
| Fee events | No fee event states this; the fee state is read from the payments the fee record holds | In force | Medium confidence |
| Further caveats on record | The record rates this date lower than the steps above account for | Low confidence overall | Low confidence |
| Computed term end | The steps above, in order | May 4, 2030 | Low confidence |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.